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Chronic periodontitis is one of the most prevalent human diseases and is caused by dysbiosis of the subgingival microbiota.
Treatment involves primarily mechanical disruption of subgingival biofilms and, in certain cases, adjunctive use of systemic an-
tibiotic therapy. In vitro biofilm models have been developed to study antimicrobial agents targeting subgingival species. How-
ever, these models accommodate a limited number of taxa, lack reproducibility, and have low throughput. We aimed to develop
an in vitro multispecies biofilm model that mimics subgingival plaque, to test antimicrobial agents. Biofilms were cultivated
using the Calgary Biofilm Device and were exposed to amoxicillin (AMX), metronidazole (MTZ), azithromycin (AZM), and
AMX-MTZ at four different concentrations for 12, 24, or 36 h. Chlorhexidine (CHX) (0.12%) was used as the positive control.
The compositions of the biofilms were analyzed by checkerboard DNA-DNA hybridization, and the percent reduction in biofilm
metabolic activity was determined using 2,3,5-triphenyltetrazolium chloride and spectrophotometry. Thirty-five of the 40 spe-
cies used in the inoculum were consistently recovered from the resulting in vitro biofilms. After 36 h of exposure at the 1:27 dilu-
tion, AMX-MTZ reduced metabolic activity 11% less than CHX (q  0.0207) but 54% more than AMX (q  0.0031), 72% more
than MTZ (q  0.0031), and 67% more than AZM (q  0.0008). Preliminary evidence of a synergistic interaction between AMX
and MTZ was also observed. In summary, we developed reproducible biofilms with 35 subgingival bacterial species, and our re-
sults suggested that the combination of AMX and MTZ had greater antimicrobial effects on these in vitro multispecies biofilms
than expected on the basis of the independent effects of the drugs.
Periodontitis is a persistent health problem that affects the U.S.population in epidemic proportions. The most recent data
from the National Health and Nutrition Examination Survey
(NHANES) (2009 to 2010) suggest that the prevalence of chronic
periodontitis among U.S. adults is over 47%, representing 64.7
million adults (1). Chronic periodontitis is the main cause of
tooth loss in adults. Treatment costs U.S. taxpayers $4.4 billion
each year (2), but existing therapies do not eradicate the disease.
Frequent posttreatment follow-up visits are needed and are costly,
which may be one reason why the prevalence is higher in popula-
tions of low socioeconomic status (3).
A single periodontal pocket harbors a complex polymicrobial
community of up to hundreds of taxa, and periodontal diseases
are triggered by dysbiosis of subgingival organisms. Organization
of the subgingival microbiota in biofilms makes it challenging to
control periodontal infections, since biofilms help protect resi-
dent organisms from both antimicrobial agents and immune
mechanisms (4). Still, the use of systemic and local antibiotics as
an adjunct to mechanical treatment provides clinical benefit be-
yond that achieved by scaling and root planing alone (5–15).
However, the threat of bacterial resistance to currently used
antibiotics raises the need to develop new agents. The first step in
such an endeavor is to demonstrate efficacy against subgingival
microorganisms in vitro, ideally in models involving organized
biofilms that respond like those in vivo. Currently used in vitro oral
multispecies biofilm models all suffer from one or more limita-
tions, generally comprising only up to 5 or 10 species (16–21). In
addition, existing models lack reproducibility and have low
throughput (17, 19).
The primary aim of this study was to develop an in vitro mul-
tispecies biofilm model that can be used to test antimicrobial
agents for their inhibition of bacterial metabolic activity. Specifi-
cally, we aimed to develop an in vitro model that mimics the com-
position and structure of subgingival plaque while also exhibiting
variability among individual biofilms and allowing for high
throughput. In part to validate the system, we compared the anti-
microbial activities of different concentrations of amoxicillin
(AMX), metronidazole (MTZ), and azithromycin (AZM), using
chlorhexidine (CHX) as the gold standard and positive control.
Using the system also allowed us to test the much-debated hy-
pothesis (22–24) that MTZ and AMX act synergistically, rather
than independently, in their antimicrobial activity against peri-
odontal pathogens.
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MATERIALS AND METHODS
Bacterial strains. The following strains were used: Actinomyces gerencse-
riae ATCC 23840, Actinomyces israelii ATCC 12102, Actinomyces naeslun-
dii ATCC 12104, Actinomyces oris ATCC 43146, Actinomyces odontolyticus
ATCC 17929, Veillonella parvula ATCC 10790, Streptococcus gordo-
nii ATCC 10558, Streptococcus intermedius ATCC 27335, Streptococcus
mitis ATCC 49456, Streptococcus oralis ATCC 35037, Streptococcus sangui-
nis ATCC 10556, Streptococcus anginosus ATCC 33397, Streptococcus mu-
tans ATCC 25175, Aggregatibacter actinomycetemcomitans ATCC 29523,
Capnocytophaga gingivalis ATCC 33624 (27), Capnocytophaga ochracea
ATCC 33596 (25), Capnocytophaga sputigena ATCC 33612 (4), Eikenella
corrodens ATCC 23834, Campylobacter concisus ATCC 33237 (484), Cam-
pylobacter gracilis ATCC 33236 (1084), Campylobacter rectus ATCC 33238
(371), Campylobacter showae ATCC 51146, Eubacterium nodatum ATCC
33099, Eubacterium saburreum ATCC 33271, Fusobacterium nucleatum
subsp. nucleatum ATCC 25586, Fusobacterium nucleatum subsp. polymor-
phum ATCC 10953, Fusobacterium nucleatum subsp. vincentii ATCC
49256, Fusobacterium periodonticum ATCC 33693, Parvimonas micra
ATCC 33270, Prevotella intermedia ATCC 25611, Prevotella nigrescens
ATCC 33563, Prevotella melaninogenica ATCC 25845, Streptococcus con-
stellatus ATCC 27823 (M32b), Tannerella forsythia ATCC 43037 (338),
Porphyromonas gingivalis ATCC 33277, Gemella morbillorum ATCC
27824, Leptotrichia buccalis ATCC 14201, Neisseria mucosa ATCC 19696,
Propionibacterium acnes ATCC 11827, and Selenomonas noxia ATCC
43541.
Media and culture conditions. Most species, including Actinomyces
subsp., Streptococcus subsp., and Fusobacterium subsp., were cultured on
tryptic soy agar with 5% sheep blood, under anaerobic conditions (85%
nitrogen, 10% carbon dioxide, and 5% hydrogen), while Eubacterium
subsp. and N. mucosa were cultivated on fastidious anaerobe agar with 5%
sheep blood, P. melaninogenica and P. gingivalis were cultured on tryptic
soy agar with yeast extract enriched with 1% hemin, 5% menadione, and
5% sheep blood, and T. forsythia was grown on tryptic soy agar with yeast
extract enriched with 1% hemin, 5% menadione, 5% sheep blood, and 1%
N-acetylmuramic acid. After 48 h of growth, all species were transferred to
glass tubes with brain heart infusion (BHI) broth (Becton Dickinson,
Sparks, MD) supplemented with 1% hemin.
Biofilm formation. After 24 h of growth in BHI broth with 1% hemin,
the optical density (OD) at 600 nm was adjusted to 0.1, corresponding to
approximately 108 cells/ml of each species. Individual cell suspensions of
each species were diluted to 107 cells/ml, with adjustment for their respec-
tive cell sizes. Aliquots of 100 l containing 106 cells of each species were
mixed to yield a final biofilm inoculum. Thirty-three milliliters of BHI
broth with 1% hemin and 5% sheep blood was added to yield a final
volume of 45 ml of inoculum. The multispecies biofilm model was devel-
oped using the Calgary Biofilm Device (CBD) (25). Three 96-well plates
(Nunc; Thermo Scientific, Roskilde, Denmark) were seeded with 150 l of
inoculum per well, containing 104 cells of each of the 40 species, and
covers with 96 polystyrene pegs were applied (Nunc TSP system; Thermo
Scientific, Roskilde, Denmark). The covered plates were then incubated at
37°C under anaerobic conditions, using the BD GasPak EZ system (Bec-
ton Dickinson, Sparks, MD). After 72 h of incubation, the covers were
transferred daily to new 96-well plates with fresh broth (BHI broth with
1% hemin and 5% sheep blood). This procedure was repeated for the next
4 days to yield 7-day biofilms on each of the 96 polystyrene pegs in each
plate. Separate plates were used for different times of exposure to antimi-
crobials (see below).
Exposure to antibiotics. The 7-day biofilms were washed twice in 200
l of rinse solution (1% phosphate-buffered saline [PBS]), and pegs from
the first column of each plate were removed to establish the baseline values
for biofilm metabolic activity and biofilm composition, as determined
with the checkerboard DNA-DNA hybridization technique (see below).
The remaining 88 pegs from each plate were exposed to different concen-
trations of AMX (catalog no. 190145; MP Biomedicals), MTZ (catalog no.
155710; MP Biomedicals), AZM (catalog no. A2076; TCI), and the com-
bination of AMX and MTZ. Starting at 108 g/ml of AMX, 270 g/ml of
MTZ, and 216 g/ml of AZM, the antibiotics were serially 3-fold diluted
to yield 4 concentrations of each antibiotic and of AMX-MTZ (1:1, 1:3,
1:9, and 1:27). CHX (Peridex [0.12% chlorhexidine gluconate]; National
Drug Code [NDC] 488788-0620-1) was used as a positive control. Pegs
coated with biofilms were washed twice with 200 l of rinse solution (1%
PBS), transferred to 96-well plates containing the different concentrations
of antibiotics, and incubated for 12, 24, or 36 h (one plate for each time
point). Each condition was tested in triplicate.
Biofilm metabolic activity. The percent reduction in biofilm meta-
bolic activity was determined using 2,3,5-triphenyltetrazolium chloride
(TTC) (catalog no. 17779; Fluka Analytical) and spectrophotometry. TTC
is used to differentiate between metabolically active and inactive cells. The
white substrate is enzymatically reduced to red 1,3,5-triphenylformazan
(TFP) by living bacterial cells, due to the activity of various dehydroge-
nases. The change in the substrate color is read by spectrophotometry to
determine the rate of reduction, which is used as an indirect measure of
bacterial metabolic activity. To measure the metabolic activity of the bio-
films, the remaining pegs were washed twice with rinse solution and trans-
ferred to plates with 200 l per well of fresh BHI broth containing 1%
hemin with 10% of a 1% TTC solution. Plates were then incubated under
anaerobic conditions for 24 h at 37°C. TTC conversion was read at 485 nm
using a fluorescence spectrophotometer (POLARstar Optima; BMG
Labtech).
Checkerboard DNA-DNA hybridization. After the TTC assay, 9 pegs
(3 pegs from each 96-well plate) covered with 7-day biofilms were washed
twice with rinse solution, extracted from the cover, and transferred to
separate Eppendorf tubes containing 100 l TE buffer (10 mM Tris-HCl,
1 mM EDTA [pH 7.6]), and then 100 l of 0.5 M NaOH was added. The
tubes containing the pegs and the final solution were boiled for 10 min,
the pegs were removed, and the solution was subsequently neutralized
with the addition of 0.8 ml of 5 M ammonium acetate. Samples were then
individually analyzed for their contents of 40 bacterial species, using the
checkerboard DNA-DNA hybridization technique (26, 27). In brief, after
the samples were lysed, the DNA was placed in lanes on a nylon membrane
using a Minislot device (Immunetics, Cambridge, MA). After fixation of
the DNA to the membrane, the membrane was placed in a Miniblotter 45
(Immunetics), with the lanes of DNA at a 90o angle with respect to the
lanes of the device. Digoxigenin-labeled whole-genome DNA probes for
40 subgingival species were hybridized in individual lanes of the Miniblot-
ter 45. After hybridization, the membranes were washed at high strin-
gency, and the DNA probes were detected using a digoxigenin-specific
antibody conjugated with alkaline phosphatase. Signals were detected us-
ing AttoPhos substrate (Amersham Life Sciences, Arlington Heights, IL),
and results were read using a Typhoon Trio Plus variable mode imager
(Molecular Dynamics, Sunnyvale, CA). Two lanes in each run contained
standards with 105 or 106 cells of each species. Signals evaluated using the
Typhoon Trio Plus variable mode imager were converted to absolute
counts by comparison with the standards on the same membrane. Failure
to detect a signal was recorded as zero. Pegs were analyzed before the
antibiotic tests, to establish baseline values.
In vivo biofilm reference values. To obtain reference values for the
composition of in vivo biofilms, we examined the database from a previ-
ous study (28). In that study, checkerboard DNA-DNA hybridization was
used to measure microbial counts of 38 of 40 species cultured in the in
vitro biofilms (C. concisus and S. mutans were not included in that study).
Up to 28 subgingival plaque samples from 178 subjects were analyzed.
Samples obtained from deep periodontal pockets (pocket depth of 5
mm) were selected from the database, and the counts (105) for each
species were averaged within subjects and then across subjects. The mi-
crobial profile obtained served as a reference for the microbial composi-
tion of mature biofilms present in deep periodontal pockets.
Calculation of minimum similarity coefficient values. We examined
the consistency of the microbial profiles across the 9 in vitro biofilm sam-
ples (3 from each 96-well plate) and between them and the in vivo refer-
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ence values by using the minimum similarity coefficient (29, 30). For this
analysis, the percentage of the total DNA probe count was calculated for
each species in each in vitro biofilm sample and for the mean reference
values for in vivo biofilms. The minimum similarity coefficient was deter-





where S is the minimum similarity coefficient, n is the number of species,
x and y are individual samples, and min(xiyi) is the smallest proportion of
a species common to both samples. For example, if a species was present at
1% in one sample and at 0.1% in a second sample, then the minimum
similarity for that species is 0.1%. Once the minimum similarity value for
each species in a pair of samples is calculated, the values are summed to
give a summary measurement for the entire microbial community.
Scanning electron microscopy. For scanning electron microscopy
(SEM), biofilms were washed with PBS, fixed with 3% (vol/vol) parafor-
maldehyde and 4% (vol/vol) glutaraldehyde in 0.1 M cacodylate buffer at
4°C, washed twice with PBS, stained with 2% osmium tetroxide, incu-
bated for 10 min in 50%, 70%, 80%, 95%, and 100% ethanol, air dried,
and sputter coated. Images of gold-coated specimens (Denton V sputter
coater; Denton, Moorestown, NJ) were obtained with a Zeiss Evo LS 10
scanning electron microscope (Carl Zeiss, Peabody, MA) in secondary
electron mode, using 30 mA for 30 s. Imaging was performed under high
vacuum at 10.00 kV, with a probe current of 3 pA and a working distance
of 25.5 mm.
Data analysis. We performed all data analyses other than calculation
of the minimum similarity index with Stata version 12 (StataCorp, Col-
lege Station, TX). For each time point, we averaged the three negative-
control OD values. We divided each assay result by this number, which
yielded the proportion of activity remaining in the presence of the antibi-
otic. We then subtracted this proportion from 1 and multiplied the result
by 100 to derive the percent inhibition. We present means and standard
deviations (SDs) for each antibiotic (or combination) at each dilution and
time point. For each dilution and time point, we also performed t tests
comparing each pair of treatments (both at the same dilution and time
point). However, we considered the primary analyses to be those for the
1:27 dilutions at 36 h, because these concentrations are likely to be closest
to those achieved in periodontal pockets when antibiotics are adminis-
tered systemically. We applied a stepdown false-discovery correction for
these 10 multiple comparisons by calculating q values, which can be in-
terpreted like P values (31). The analyses for the remaining dilutions and
time points are considered exploratory, but we also calculated corrected q
values over all 144 comparisons, for benchmarking purposes (data not
shown).
To estimate potential synergy between AMX and MTZ, the observa-
tions in each triplicate determination were treated as separate indepen-
dent observations in a linear regression model in which percent inhibition
was the dependent variable, separate indicators were used to specify the
presence or absence of AMX and MTZ, and the combination of antibiotics
was entered as a multiplicative interaction term. One way to interpret the
interaction term is as the difference in AMX effects in the presence versus
absence of MTZ, or vice versa. The interaction P value is from a test of the
null hypothesis that AMX effects (AMX versus placebo) are the same
regardless of whether MTZ is present or absent, and vice versa. Combined
exposure to two effective agents should always increase the effects, even in
the absence of synergy; the question posed here is whether the combined
effects are greater than would be expected on the basis of two independent
effects acting concurrently. For these analyses, we also estimated 95%
confidence intervals (CIs) and performed two-sided tests with alpha at
0.05. We did not adjust for multiple comparisons, again considering the
primary analyses to be those for the 1:27 dilutions at 36 h and analyses for
all other time points and concentrations to be secondary.
RESULTS
Minimum similarity coefficient values. There was a high degree
of similarity in the compositions of in vitro biofilms across pegs
and plates (Fig. 1). For instance, the minimum similarity coeffi-
cients among pegs from plate I were 79, 80, and 97, depending on
which pairs of pegs were being compared. Plates II and III had
minimum similarity coefficient values ranging from 77 to 93.
When pegs from different plates were compared, minimum sim-
ilarity coefficient values were also high, ranging from 70 to 88.
Lower minimum similarity coefficient values were obtained when
the compositions of in vitro biofilms were compared with the ref-
erence values for in vivo biofilms; however, values were consistent
across the 9 pegs examined, ranging from 37 to 46.
Compositions of 7-day in vitro biofilms and in vivo biofilms.
Five of the 40 species used in the inoculum, i.e., P. intermedia, P.
nigrescens, T. forsythia, P. acnes, and P. melaninogenica, could not
be consistently recovered from the biofilms that formed on the
pegs (Fig. 2). The remaining 35 species, including putative peri-
odontal pathogens such as A. actinomycetemcomitans, E. nodatum,
F. nucleatum subsp. nucleatum, F. nucleatum subsp. polymor-
phum, F. periodonticum, P. micra, and P. gingivalis, were consis-
tently recovered. The reference values for the in vivo biofilms dem-
onstrated that several species clearly outgrew others in levels not
observed in vivo (Fig. 2). For instance, V. parvula, S. mitis, S. san-
guinis, C. showae, F. nucleatum subsp. polymorphum, and F. nu-
cleatum subsp. vincentii achieved counts that were 5 times
greater than those observed in periodontitis subjects. In addition,
S. oralis, G. morbillorum, and N. mucosa achieved levels at least
10-fold greater than those observed in humans, while S. interme-
dius, E. corrodens, and S. anginosus reached counts that were at
least 20 times higher than those in in vivo subgingival samples. The
density and complexity of the biofilms were also demonstrated by
the SEM images; different cell shapes were observed (Fig. 3).
Reductions in metabolic activity with antibiotics, as mea-
sured by TTC conversion. In the experiments to measure antimi-
crobial activity using TTC conversion, the positive control, 0.12%
CHX, decreased metabolic activity by approximately 95% at all
three exposure times (i.e., 12, 24, and 36 h) (Table 1). All of the
FIG 1 Matrix of minimum similarity coefficient values for the microbial pro-
files for 9 in vitro biofilms from three 96-well plates (plate I, plate II, and plate
III) and for these in vitro biofilms versus mean values for in vivo biofilms from
178 subjects. Cells with thicker borders include minimum similarity coeffi-
cient values for comparisons among biofilms from the same plate.
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antibiotics induced dose-dependent decreases in microbial activ-
ity at all three time points; the only exception was AMX-MTZ at
the 1:27 dilution at 24 h. Chlorhexidine reduced metabolic activity
more strongly than did most antimicrobials tested at the higher
dilutions (i.e., 1:9 and 1:27) (Table 1). In comparisons of the an-
tibiotics or the combination versus others at 36 h, at dilutions of
1:27, AMX-MTZ reduced metabolic activity 11% less than CHX
(q  0.0207) but 54% more than AMX (q  0.0031), 72% more
than MTZ (q  0.0031), and 67% more than AZM (q  0.0008)
(Table 2).
Interaction between metronidazole and amoxicillin. At 36 h,
at the dilution of 1:27, AMX in the absence of MTZ induced inhi-
bition of 30% (95% confidence interval [CI], 12% to 47%). In the
presence of MTZ, this effect increased to 72% (95% CI, 55% to
90%; interaction P  0.01). MTZ exhibited little to no inhibitory
activity in the absence of amoxicillin (95% CI, 6% to 30%) but
FIG 2 Mean levels (counts  105) of the 40 subgingival species in 7-day biofilms grown in the CBD. Values represent the means for 3 pegs processed with
checkerboard DNA-DNA hybridization for each 96-well plate, and the error bars indicate the standard errors of the mean. The species were ordered according
to the microbial complexes described by Socransky et al. (45). The red lines illustrate the mean microbial profile of mature in vivo biofilms present in deep
periodontal pockets.
FIG 3 Scanning electron micrographs of biofilms formed on the pegs of the CBD.
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achieved 54% inhibition in the presence of amoxicillin (95% CI,
37% to 72%; interaction P  0.01) (Table 3).
Both the dose-response relationships for individual antibiotics
and the synergistic interaction were observed at 36 h (Tables 2 and
3). At their highest concentrations, we observed an antagonistic
interaction between the two antibiotics at 36 h (Table 3); that is,
each antibiotic exhibited less inhibitory activity in the presence of
the other antibiotic than when used alone.
DISCUSSION
We described an in vitro multispecies biofilm model that mimics
the composition and structure of subgingival plaque. The model
presents several advantages over previously existing models (16–
21), in that we were able to consistently establish 35 species, com-
pared with the previous maximum of 5 to 10 species (18, 20, 21).
Further, the Calgary Biofilm Device afforded a high-throughput
system to grow several repeats of biofilms with good consistency
across pegs and plates, as evidenced by the high minimum simi-
larity coefficient values. We used growth conditions (specifically
regarding the medium and atmosphere) designed to reproduce
the environmental conditions found in the subgingival habitat of
deep periodontal pockets. Parameters such as the presence of sa-
liva or some of its constituents, pH, and surface coatings (e.g.,
L-lysine) were tested during optimization of the model. We also
provided evidence that the in vitro biofilms share characteristics of
in vivo biofilms. For example, SEM images demonstrated dense
complex biofilms on the pegs of the CBD. Well-established peri-
odontal pathogens such as A. actinomycetemcomitans, E. nodatum,
F. nucleatum subsp. nucleatum, F. nucleatum subsp. polymor-
phum, F. periodonticum, P. micra, and P. gingivalis were consis-
tently recovered from the formed biofilms, which, in addition to
validating the model conditions, allows for testing of antimicro-
bials targeting these species.
Some features of the multispecies biofilm limit its potential
uses, however. For example, we did not recover several known
TABLE 1 Reduction of metabolic activity after exposure to antibiotics at different concentrations and incubation times
Time and
dilution
% reduction of metabolic activity (mean  SD) after exposure toa:
CHX MTZ AMX AZM AMX-MTZ
12 h
1:1 94.2  1.2 40.8  2.6 90.4  1.9 84.9  7.7 93.4  0.5
1:3 22.0  17.4 37.3  20.2 48.4  32.4 71.5  33.4
1:9 18.5  7.3 13.0  32.5 21.6  37.4 77.4  13.5
1:27 14.5  9.4 0.4  32.0 0.5  5.7 67.3  25.1
24 h
1:1 94.8  0.6 53.7  3.3 64.0  31.8 58.6  28.8 60.8  46.1
1:3 37.7  8.7 37.8  27.2 33.8  15.5 69.3  23.6
1:9 23.8  3.4 8.5  9.2 21.5  7.9 56.9  45.6
1:27 31.0  8.1 25.3  10.3 13.3  6.4 16.0  12.9
36 h
1:1 95.3  0.2 40.7  18.6 93.7  0.2 90.1  5.4 94.3  0.2
1:3 20.6  42.2 88.8  5.5 50.4  60.7 92.5  0.4
1:9 39.7  9.7 43.7  11.8 13.0  6.4 82.5  2.5
1:27 12.0  16.4 29.8  11.4 17.3  7.0 84.1  4.6
a CHX, chlorhexidine; MTZ, metronidazole; AMX, amoxicillin; AZM, azithromycin; SD, standard deviation.
TABLE 2 Results of pairwise t tests comparing one drug (or combination) to another
Antibiotic(s) compared and
parametera CHX AMX MTZ AZM
AMX
% mean difference (95% CI) 65 (47–84)
q 0.0020
MTZ
% mean difference (95% CI) 83 (57–109) 18 (14 to 50)
q 0.0023 0.2188
AZM
% mean difference (95% CI) 78 (67–89) 13 (9 to 34) 5 (34 to 23)
q 0.0004 0.2188 0.6319
AMX-MTZ
% mean difference (95% CI) 11 (4–18) 54 (74 to 35) 72 (99 to 45) 67 (80 to 53)
q 0.0207 0.0031 0.0031 0.0008
a All results were assessed at 36 h, at dilutions of 1:27. CHX, chlorhexidine; AMX, amoxicillin; MTZ, metronidazole; AZM, azithromycin; CI, confidence interval.
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periodontal pathogens, specifically P. intermedia, P. nigrescens, T.
forsythia, P. acnes, and P. melaninogenica, presumably because
they failed to grow in the biofilms. Furthermore, in comparing
counts of species recovered to levels reported for 178 subjects (28),
we inferred that several species acted as microbial weeds and
clearly outgrew other species at levels not observed in vivo. These
differences resulted in relatively low minimum similarity coeffi-
cient values for the microbial profiles of in vitro and in vivo bio-
films. In addition to raising general concerns about the applica-
bility of the model to humans, these differences might have
influenced the results of the specific experiment we conducted.
For instance, the failure to recover several Prevotella species might
have increased the tolerance of the biofilms to metronidazole,
which specifically targets strict anaerobic Gram-negative bacteria.
Furthermore, Treponema species were also excluded from the in
vitro model, due to difficulties in the growth of these strict anaer-
obes.
At any given time, a single periodontal pocket harbors an av-
erage of 100 species, of 300 possible colonizers. Many of these
species necessarily occur in very small proportions (32, 33). We
selected 40 species that are among the most abundant and that
collectively account for approximately 60% of the subgingival bio-
film mass (34), and the number of species recovered, i.e., 35, is
much greater than that achieved in other currently used biofilm
models.
Conversion of TTC has been used as a test to measure the levels
of metabolic activity of bacterial cells grown planktonically or as
biofilms and can be used as a surrogate for cell viability (35–39).
Chlorhexidine decreased the metabolic activity of the biofilms by
approximately 95%  0.8% (mean  SD) at all exposure times
(12, 24, and 36 h), demonstrating its appropriateness as a positive
control. At the primary time point (36 h) and the most physiolog-
ically relevant concentration (1:27 dilution), the combination of
AMX and MTZ had greater antimicrobial effects than would be
expected if the two drugs were working independently. Even at
concentrations for which there was little statistical evidence of
synergy, the additive effects still afforded enhanced antimicrobial
activity. For most dilutions and time points tested, the combina-
tion of AMX and MTZ gave results similar to those obtained
with CHX.
We identified the 1:27 dilutions as being of primary interest
because they corresponded to levels obtained in gingival crevicu-
lar fluid (GCF) with the systemic use of these agents, i.e., 4, 10, and
8 g/ml for AMX, MTZ, and AZM, respectively (40–42). How-
ever, we also tested higher concentrations to examine whether
they had increased efficacy. It has been argued that the superiority
of the combination of AMX and MTZ over MTZ alone observed
in clinical trials (6, 8, 12–14) could be the consequence of an
overall higher dosage of antibiotics, rather than a synergistic anti-
microbial mechanism. Even at levels 27-fold higher than those
typically obtained clinically, however, MTZ did not decrease the
metabolic activity of the biofilms to levels achieved with the com-
bination of AMX and MTZ. Similarly, AMX alone required con-
centrations 9 to 27 times higher than the combination to achieve
greater reductions in the metabolic activity of the biofilms. Thus,
these data are inconsistent with additive effects of AMX and MTZ
and are more consistent with synergistic effects of these antimi-
crobials.
A possible explanation for the synergistic effects of metronida-
zole and amoxicillin may be increased uptake of metronidazole in
the presence of amoxicillin, as has been described for A. actinomy-
cetemcomitans (23). Furthermore, metronidazole is effective
against species from the anaerobic genus Prevotella, which are
capable of producing beta-lactamases (43). Therefore, another
potential synergistic mechanism would be enhancement of
amoxicillin activity in the presence of metronidazole due to de-
creases in the levels of beta-lactamases. Our findings provide ad-
TABLE 3 Interactions between AMX and MTZ at different concentrations at 36 h of incubation
Dilution
Drug treatment and parametera 1:1 1:3 1:9 1:27
AMX in absence of MTZ
Difference in % inhibition (95% CI) 0.94 (0.78–1.10) 0.89 (0.54–1.23) 0.44 (0.30–0.58) 0.30 (0.12–0.47)
P 0.0005 0.0005 0.0005 0.01
AMX in presence of MTZ
Difference in % inhibition (95% CI) 0.54 (0.37–0.70) 0.72 (0.37–1.07) 0.43 (0.29–0.57) 0.72 (0.55–0.90)
P 0.0005 0.0005 0.0005 0.0005
Interaction Pb 0.01 0.52 0.93 0.01
MTZ in absence of AMX
Difference in % inhibition (95% CI) 0.41 (0.25–0.57) 0.21 (0.14 to 0.55) 0.40 (0.26–0.54) 0.12 (0.06 to 0.30)
P 0.0005 0.28 0.0005 0.22
MTZ in presence of AMX
Difference in % inhibition (95% CI) 0.01 (0.16 to 0.17) 0.04 (0.31 to 0.38) 0.39 (0.25–0.53) 0.54 (0.37–0.72)
P 0.94 0.84 0.0005 0.0005
Interaction Pb 0.01 0.52 0.93 0.01
a A linear regression model was used, and the dependent variable was percent inhibition. AMX, amoxicillin; MTZ, metronidazole; CI, confidence interval.
a Interaction P value comparing absence or presence of the second drug.
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ditional support for the use of such drugs in the treatment of
periodontal diseases.
In vitro biofilm models have been proposed as a means to ex-
amine the higher tolerance to antimicrobials that this mode of
growth confers to bacteria (4). It has been argued that, due to
greater tolerance to antimicrobials, MICs calculated using bacte-
rial cells grown planktonically would bear little relevance to in vivo
situations (25). The higher tolerance of biofilms to antimicrobials
has also led periodontists to recommend that the use of these
agents be accompanied or preceded by mechanical disruption of
the subgingival biomass. This notion was challenged by a clinical
study that demonstrated that the use of systemic AMX-MTZ ther-
apy without subgingival debridement could lead to clinical im-
provements and changes in the subgingival microbiota similar to
those obtained with mechanical therapy (i.e., scaling and root
planing) (44). Here we provide additional support for the notion
that AMX-MTZ, at concentrations observed in GCF after systemic
administration, can significantly reduce the metabolic activity of
subgingival bacterial species even when they are organized in
complex biofilms. In conclusion, reproducible biofilms with 35
subgingival bacterial species were developed, and the combina-
tion of AMX and MTZ had greater antimicrobial effects on these
in vitro multispecies biofilms than expected on the basis of the
independent effects of the drugs.
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